Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
One trial provided data for the intravenous administration of semaglutide and also used different drug product strengths (see further descriptions in the Methods section of the Electronic supplementary material, ESM)
Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, et al
FEP formulary prescription drug list and costs, Blue Cross Blue Shield Blue Cross and Blue Shield system, BCBS Semaglutide, StatPearls (2024) Rybelsus prescribing information, Novo Nordisk (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
About the SELECT Trial 7 SELECT was a randomized, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for prevention of major adverse cardiovascular outcomes (MACE) in people with established cardiovascular disease with overweight or obesity with no prior history of diabetes
US$ 20.13
US$ 25.87
US$ 29.74
US$ 20.73
